Oppose the Most Favored Nation Interim Final Rule
- FLASCO
- January 8, 2021
- News
The Florida Society of Clinical Oncology has opposed the MFN Model since its release and is pleased it did not go into effect on January 1. However, given the devastating impact the model would have on people with cancer, ASCO will continue to advocate for a full withdrawal of the proposal.
CMS estimates that the MFN Model will cause 19% of Medicare beneficiaries to lose access to the model’s 50 targeted drugs, 38 of which are used to treat cancer. ASCO’s analysis finds that reimbursement cuts to just four drugs commonly used to treat lung and other cancers would result in patients with lung cancer losing as many as 87,556 years of life due to their loss of access to these drugs over the model’s seven-year duration.
FLASCO has submitted comments to CMS, strongly opposing MFN and have urged the Centers for Medicare and Medicaid Services (CMS) to immediately withdraw this rule and not move ahead with MFN Model implementation. You can submit individual comments to CMS using this ACT Network alert
